

REMARKS

Reconsideration is respectfully requested. Claim 60 has been cancelled. Claims 1-55, 57-59, and 61-85 are pending.

With respect to all cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter to the public. Applicants reserve the right to pursue prosecution of any presently excluded claim embodiments in future continuation and/or divisional applications.

Restriction Requirement

The Examiner requires elections from between Groups I and II. Group I (claims 1-55, 57-59, and 61-85) is directed to polypeptides, while Group II (claim 60) is directed to methods of using the polypeptides.

Applicants elect Group I (claims 1-55, 57-59, and 61-85) **without traverse**. Applicants have cancelled claim 60.

Election of Species

The Examiner requires multiple elections of species, summarized as (I) – (IV) below.

The Election of Species Requirements

- I. The Examiner requires an election of species between
 - A) an antibody or
 - B) an immunoadhesin (e.g. paragraph [083] of the instant patent application).
- II. The Examiner further states that if the antibody species is elected, then the Examiner requires a further election of one specific target (e.g. CD4 recited in claims 61-66).
- III. The Examiner further requires election of one specific polypeptide species comprising an Fc variant with the following information
 - A. specific antibody subtype;
 - B. a specific substitution in the Fc region with specific amino acid residues; and
 - C. any functional limitations recited that are encompassed by the elected polypeptide species.

IV. The Examiner further requires election of one polypeptide comprising an Fc variant that is

- A. no carbohydrate modification;
- B. a glycosylated Fc, or
- C. an engineered glycoform.

Applicants' Election

Applicants elect the species as follows, each **without traverse**:

- I. Applicants elect an antibody. All pending claims read on this elected species.
- II. With respect to the target, Applicants elect CD20. Claims 61-66, 75, 78 and 85 read on this elected species.
- III. With respect to the specific polypeptide sequences, Applicants elect:
 - A. IgG1. Claims 69 and 71 read on this elected species.
 - B. Position 239 and substitutions 239D. Claims 7, 8, 15, 16, 27, 28, 40, 41, 53, 54 and 63 read on this elected species.
 - C. Increased affinity for Fc γ R. Claims 1-33, 57-59, and 79-84 read on this elected species.
- IV. Applicants elect no carbohydrate modification. Claims 47-55 read on this elected species.

Applicants note that the above elections are election of species, not elections of a restricted group. Accordingly, after the elected species have been determined to be free of the art, Applicants respectfully request that the Examiner continue to search species that are not elected in the present election.

Conclusion

In light of the above amendments and remarks, Applicant believes that this case is now in condition for allowance. Early notification is respectfully requested. Should there be any remaining issues that remain unresolved, the Examiner is encouraged to telephone the undersigned.

Attorney Docket No. A-71386-7 463077-243
Serial No. 10/672,280
Filed: September 26, 2003



Please direct further questions in connection with this Application to the undersigned at
(415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY LLP

Dated: May 22, 2006
555 California Street, Suite 1000
San Francisco, California 94104-1513
Telephone: (415) 781-1989
Fax No. (415) 398-3249

By: [Signature]
Timothy A. Worrall, Reg. No. 54,552
for Robin M. Silva, Reg. No. 38,304

Filed under 37 C.F.R. § 1.34 (a)